Literature DB >> 24395289

Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy.

Christopher Spurney1, Reiko Shimizu, Lauren P Morgenroth, Hanna Kolski, Heather Gordish-Dressman, Paula R Clemens.   

Abstract

INTRODUCTION: Cardiomyopathy is a common cause of morbidity and death in patients with Duchenne muscular dystrophy (DMD).
METHODS: This investigation was a cross-sectional cross-sectional analysis of clinical data from the multi-institutional Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study of 340 DMD patients aged 2-28 years. Cardiomyopathy was defined as shortening fraction (SF) <28% or ejection fraction (EF) <55%.
RESULTS: Two hundred thirty-one participants reported a prior clinical echocardiogram study, and 174 had data for SF or EF. The prevalence of cardiomyopathy was 27% (47 of 174), and it was associated significantly with age and clinical stage. The association of cardiomyopathy with age and clinical stage was not changed by glucocorticoid use as a covariate (P > 0.68). In patients with cardiomyopathy, 57% (27 of 47) reported not taking any cardiac medications. Cardiac medications were used in 12% (15 of 127) of patients without cardiomyopathy.
CONCLUSIONS: We found that echocardiograms were underutilized, and cardiomyopathy was undertreated in this DMD natural history cohort.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Duchenne muscular dystrophy; cardiomyopathy; echocardiogram; glucocorticoid; natural history

Mesh:

Substances:

Year:  2014        PMID: 24395289      PMCID: PMC4081523          DOI: 10.1002/mus.24163

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  36 in total

1.  Cardioprotection for Duchenne's muscular dystrophy.

Authors:  Y Ishikawa; J R Bach; R Minami
Journal:  Am Heart J       Date:  1999-05       Impact factor: 4.749

2.  107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

Authors:  K Bushby; F Muntoni; J P Bourke
Journal:  Neuromuscul Disord       Date:  2003-02       Impact factor: 4.296

3.  Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy.

Authors:  J GILROY; J L CAHALAN; R BERMAN; M NEWMAN
Journal:  Circulation       Date:  1963-04       Impact factor: 29.690

4.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

5.  Clinical trial in Duchenne dystrophy. I. The design of the protocol.

Authors:  M H Brooke; R C Griggs; J R Mendell; G M Fenichel; J B Shumate; R J Pellegrino
Journal:  Muscle Nerve       Date:  1981 May-Jun       Impact factor: 3.217

6.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

7.  Evidence-based path to newborn screening for Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Chris Shilling; Nancy D Leslie; Kevin M Flanigan; Roula al-Dahhak; Julie Gastier-Foster; Kelley Kneile; Diane M Dunn; Brett Duval; Alexander Aoyagi; Cindy Hamil; Maha Mahmoud; Kandice Roush; Lauren Bird; Chelsea Rankin; Heather Lilly; Natalie Street; Ram Chandrasekar; Robert B Weiss
Journal:  Ann Neurol       Date:  2012-03       Impact factor: 10.422

Review 8.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

9.  Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Larry W Markham; Kathi Kinnett; Brenda L Wong; D Woodrow Benson; Linda H Cripe
Journal:  Neuromuscul Disord       Date:  2008-04-23       Impact factor: 4.296

10.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

View more
  34 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Myocardial Strain Using Cardiac MR Feature Tracking and Speckle Tracking Echocardiography in Duchenne Muscular Dystrophy Patients.

Authors:  Bryan Siegel; Laura Olivieri; Heather Gordish-Dressman; Christopher F Spurney
Journal:  Pediatr Cardiol       Date:  2017-11-29       Impact factor: 1.655

3.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

4.  Reduced serum myostatin concentrations associated with genetic muscle disease progression.

Authors:  Peter M Burch; Oksana Pogoryelova; Joe Palandra; Richard Goldstein; Donald Bennett; Lori Fitz; Michela Guglieri; Chiara Marini Bettolo; Volker Straub; Teresinha Evangelista; Hendrik Neubert; Hanns Lochmüller; Carl Morris
Journal:  J Neurol       Date:  2017-01-10       Impact factor: 4.849

5.  Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies.

Authors:  Christopher F Spurney; Francis M McCaffrey; Avital Cnaan; Lauren P Morgenroth; Sunil J Ghelani; Heather Gordish-Dressman; Adrienne Arrieta; Anne M Connolly; Timothy E Lotze; Craig M McDonald; Robert T Leshner; Paula R Clemens
Journal:  J Am Soc Echocardiogr       Date:  2015-04-21       Impact factor: 5.251

6.  Electrocardiographic and echocardiographic findings in muscular dystrophy patients with heart failure.

Authors:  Masataka Ogiso; Toshiaki Isogai; Ken Kato; Hiroyuki Tanaka; Tamotsu Tejima; Eiji Isozaki
Journal:  Heart Vessels       Date:  2018-05-15       Impact factor: 2.037

7.  Cardiac Phenotype-Genotype Associations in DMD/BMD: A Meta-Analysis and Systematic Review.

Authors:  Huan Zhou; Manli Fu; Bing Mao; Li Yuan
Journal:  Pediatr Cardiol       Date:  2020-10-09       Impact factor: 1.655

Review 8.  Duchenne muscular dystrophy: the management of scoliosis.

Authors:  James E Archer; Adrian C Gardner; Helen P Roper; Ashish A Chikermane; Andrew J Tatman
Journal:  J Spine Surg       Date:  2016-09

9.  Creation of a novel algorithm to identify patients with Becker and Duchenne muscular dystrophy within an administrative database and application of the algorithm to assess cardiovascular morbidity.

Authors:  Jonathan H Soslow; Matthew Hall; W Bryan Burnette; Kan Hor; Joanne Chisolm; Christopher Spurney; Justin Godown; Meng Xu; James C Slaughter; Larry W Markham
Journal:  Cardiol Young       Date:  2019-01-26       Impact factor: 1.093

Review 10.  Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Authors:  David G Allen; Nicholas P Whitehead; Stanley C Froehner
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.